Clinical trials: Human Immunodeficiency Virus II Infection
HIV Infection Associated Kaposi Disease
Lenalidomide in Kaposi Disease Associated With HIV Infection
Lenakap : This multicenter, non randomized (single arm), open, phase II study aims to evaluated the efficacy of Lenalidomide in HIV-associated kaposi disease. Patients will be followed for 48 weeks.
- Trial name
- LENAKAP (NCT01282047)
- Testing
- Lenalidomide
- Where
- France
- Volunteers
- 12 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Healthy, HIV Infection
Safety and Anti-HIV Activity of Capravirine Alone and in Combination With Other Anti-HIV Drugs
This 2-part study will test the safety and anti-HIV activity of capravirine alone, and the safety, anti-HIV activity, and drug interactions of capravirine combined with other anti-HIV drugs.
- Trial name
- NCT00005673
- Testing
- Capravirine
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, BK Virus Infection
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus.
- Conditions
- Acquired Immunodeficiency Syndrome, BK Virus Infection, Human Immunodeficiency Virus, JC Virus Infection
- Trial name
- NCT02479698
- Testing
- Allogeneic BK-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Cryptococcal Meningitis
Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis
This study will examine the effectiveness and safety of a combination treatment for cryptococcal meningitis, a fungal infection common in persons with acquired immune deficiency syndrome (AIDS) in the developing world.
- Trial name
- NCT00145249
- Testing
- Amphotericin B, Fluconazole
- Where
- 15 sites in United States, Thailand
- Volunteers
- 143 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs
The purpose of this study is to look at the safety and effectiveness of receiving lamivudine (3TC) once a day versus twice a day as part of an anti-HIV drug combination.
- Trial name
- NCT00004852
- Testing
- Efavirenz, Lamivudine, Zidovudine
- Where
- 66 sites in United States, Argentina and 3 more
- Sponsor
- Glaxo Wellcome
HIV Infection
TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use
The purpose of this study is to determinate the effectiveness, safety and tolerability (how well the body accepts the drug) of an investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) called TMC125.
- Trial name
- NCT00225303
- Testing
- TMC125
- Volunteers
- 116 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone
To compare two different routes of intermittently administered rhIL-2 with a highly active antiretroviral regimen (HAART) to HAART alone.
- Trial name
- NCT00000870
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 20 sites in United States
- Volunteers
- 200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL
This multicenter, international, non randomized (single arm), open, phase II trial aims to evaluate the capacity of the dual combination raltegravir/etravirine to maintain virological success in virologically suppressed HIV-1…
- Trial name
- NCT02212379
- Testing
- raltegravir and etravirine
- Where
- 19 sites in France, Spain
- Volunteers
- 170 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1
An Efficacy and Safety Study of Autologous Cluster of Differentiation 34 (CD34+) Hematopoietic Progenitor Cells Transduced With Placebo or an Anti- Human Immunodeficiency Virus Type 1 (HIV-1) Ribozyme (OZ1) in Participants With HIV-1 Infection
The purpose of this study is to determine the safety and efficacy of administration of a cell-delivered ribozyme gene transfer product to participants with chronic (lasting a long time) Human Immunodeficiency Virus Type 1 (HIV-1)…
- Trial name
- NCT00074997
- Testing
- OZ1, CD34+ cells
- Where
- Australia
- Volunteers
- 1 people
- Sponsor
- Janssen-Cilag Pty Ltd
AIDS, HIV Infections
Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)
This study will test the safety and efficacy of an investigational Human Immunodeficiency Virus (HIV) vaccine. Efficacy will be measured by either prevention of HIV infection or control of HIV viral load in subjects who become…
- Trial name
- NCT00095576
- Testing
- Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection
To determine the relative antiviral activity and safety of zidovudine ( AZT ) and didanosine ( ddI ) alone and in combination, as well as in various sequences of administration.
- Trial name
- NCT00000823
- Testing
- Zidovudine, Didanosine
- Where
- 22 sites in United States
- Volunteers
- 85 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients
To compare the long-term virologic response to combination therapy with two protease inhibitors, i.e., nelfinavir (NFV) + saquinavir soft gel capsule (SQVsgc) and delavirdine (DLV) or combination lamivudine/zidovudine (3TC/ZDV…
- Trial name
- NCT00001094
- Testing
- Lamivudine/Zidovudine, Nelfinavir mesylate, Saquinavir
- Where
- 17 sites in United States, Puerto Rico
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)
This multicenter, open-label, noncomparative study evaluates two oral formulations of raltegravir (MK-0518, film-coated tablet and chewable tablet) in combination with other antiretroviral agents for safety, tolerability, and…
- Trial name
- NCT01717287
- Testing
- Raltegravir Film-coated Tablet, Raltegravir Chewable Tablet, Other Anti-Retroviral Therapy
- Volunteers
- 32 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
The purpose of this study is to evaluate the safety and tolerability of giving IL-2 plus anti-HIV (antiretroviral) therapy to HIV-positive patients with CD4 cell counts (cells of the immune system that fight infection) of at…
- Trial name
- NCT00000948
- Testing
- Aldesleukin, ART
- Where
- 2 sites in Thailand
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients
This study evaluate the safety of UB-421 in combination with standard antiretroviral therapy (ART) and the efficacy of HIV reservoir reduction as compared with ART alone in ART stabilized HIV-1 patients
- Trial name
- NCT03743376
- Testing
- UB-421(25 mg/kg) Q2W, UB-421(25 mg/kg) Q4W
- Where
- 3 sites in Taiwan
- Volunteers
- 31 people
- Sponsor
- United BioPharma
Human Immunodeficiency Virus (HIV)
Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
This is a multi-site, double-blinded, two-arm, two:one, randomized, trial comparing the safety of an intramuscular (IM) injection of TMC278 LA to a placebo given once every eight weeks over a 40 week period among sexually active…
- Trial name
- TMC278LA (NCT02165202)
- Testing
- Rilpivirine
- Where
- 4 sites in United States, South Africa and 1 more
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- PATH
HIV Infections
A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects
To evaluate the safety and immunogenicity of a combination of microparticulate monovalent HIV-1 MN synthetic branched peptide candidate vaccine for oral administration and monovalent HIV-1 MN synthetic branched peptide vaccine in…
- Trial name
- NCT00002428
- Testing
- HIV-1 Peptide Vaccine, Microparticulate Monovalent, rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- United Biomedical
HIV Infections, Cachexia
Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women
OBJECTIVES: I. Determine whether physiologic testosterone replacement can increase fat-free mass, therefore contributing to weight maintenance, improved muscle function, and quality of life in HIV-infected women. II.
- Trial name
- NCT00004400
- Testing
- testosterone
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Charles Drew University of Medicine and Science
HIV Infections, Sexually Transmitted Diseases
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
Human papillomavirus (HPV) is the most common sexually transmitted disease in the world. HPV infection can cause genital warts and certain cervical problems, including cervical cancer.
- Trial name
- NCT00604175
- Testing
- Quadrivalent HPV vaccine
- Where
- 61 sites in United States, Brazil and 2 more
- Volunteers
- 319 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus, Herpes Simplex Type II
MAMAS: Mentoring Adolescent Mothers at School
This study aims to evaluate the efficacy of an intervention designed to reduce STI/HIV incidence by increasing the number of adolescent mothers who re-enroll and remain in school.
- Conditions
- Human Immunodeficiency Virus, Herpes Simplex Type II, Chlamydia, Gonorrhea
- Trial name
- MAMAS (NCT03090802)
- Testing
- Mentoring Adolescent Mothers at School (MAMAS)
- Where
- South Africa
- Volunteers
- 152 people
- Sponsor
- Drexel University